ClinicalTrials.gg
RecruitingNCT07228039Updated Nov 6, 2026

ESP Blocks for Posterior Spinal Fusion

A Phase 4 interventional study of ESP Block with Bupivacaine and ESP Block with Bupivacaine + Liposomal Bupivacaine in Postoperative Pain, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Duke University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Pain, Postoperative by Duke University — 6 open to participants now, 6 under way, none of them phase 3. Pain, Postoperative · Duke University.

Planned enrollment
7th of 17
75 · median 53
Started
2026
with 3 others
Phase 4
11 of 19
5 open now
Registered
16th of 19
by date

Among the 19 studies in Pain, Postoperative by Duke University, this one is the 7th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2026, is one of 11 in phase 4, and was the 16th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

6 of the 19 studies in Pain, Postoperative by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pain, Postoperative by Duke University, or all of them as a file.
02

Study summary

This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • ESP Block
  • Spinal Fusion
  • Multimodal Analgesia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking
  • Age 18-75
  • 1-3
  • Undergoing elective cervical or lumbar posterior spinal fusion (≤3 levels)

Exclusion criteria

Exclusion Criteria

  • Age \<18 or >75
  • Non-English speaking
  • >40
  • Opioid dependence
  • Chronic pain
  • Anticoagulation or coagulopathy
  • Injection site infection
  • Hepatic or renal insufficiency
  • Allergy to study drugs
  • Pregnancy
  • Inability to communicate with investigators
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    ESP + Liposomal Bupivacaine

    Group 1 receives ESP block with 0.5% bupivacaine plus liposomal bupivacaine.

    Drug: ESP Block with Bupivacaine + Liposomal Bupivacaine

  • Experimental
    ESP + Plain Bupivacaine

    Group 2 receives ESP block with 0.5% plain bupivacaine.

    Drug: ESP Block with Bupivacaine

Interventions

  • DrugESP Block with Bupivacaine

    Cervical and lumbar ESP blocks performed under ultrasound guidance using plain bupivacaine.

  • DrugESP Block with Bupivacaine + Liposomal Bupivacaine

    Cervical and lumbar ESP blocks performed under ultrasound guidance using bupivacaine admixed with liposomal bupivacaine.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain as measured by opiate consumption

    Morphine MilliEquivalents

    Time frame: 72 hours

Secondary outcomes

  1. Postoperative Pain at rest and with movement as measured by patient reported pain scores

    Numeric Rating Scale (0-10) 0 being no pain, 10 being worst pain imaginable

    Time frame: 4, 8, 12, 24, 48, and 72 hours

  2. Discharge Readiness

    Hospital and PACU Length of Stay

    Time frame: 72 hours

  3. Postoperative Pain Severity as measured by required time for patient controlled-analgesia

    Duration of patient controlled analgesia use

    Time frame: 72 hours

  4. Incidents of post-operative nausea and vomiting

    Post-operative Nausea and Vomiting

    Time frame: 72 hours

  5. Time to first ambulation

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 16 months is close to that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

Start moved once since we started tracking on Sep 25, 2026: Oct 2027 → Sep 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2025
First posted
Nov 13, 2025
StartActual
Sep 17, 2026was Oct 2027
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
Duke University is now Recruiting
Oct 26, 2026
Start date
Oct 2027→Sep 17, 2026 (actual)
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Duke University · Durham, United StatesContact added s•••@duke.edu · •••9894
Oct 26, 2026
Show all 2 updates
  1. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 26, 2026
    Not yet recruiting→Recruiting
    Duke University is now Recruiting
    Start date Oct 2027→Sep 17, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Duke University · Durham, United StatesContact added s•••@duke.edu · •••9894

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07228039
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Nov 13, 2025
Start date
Sep 17, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Stephen Davies
principal investigator · Duke University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion